SciSparc Ltd. Finalizes Agreement with Miza III Ventures for Asset Transfer
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
SciSparc Ltd. ( (SPRC) ) has provided an update.
On October 9, 2025, SciSparc Ltd. entered into an agreement with Miza III Ventures Inc. to transfer its pharmaceutical portfolio and a 50.9% equity stake in SciSparc Nutraceuticals Inc. to Miza in exchange for a controlling interest in Miza. This transaction is valued at approximately CAD 15.8 million and is expected to close by October 22, 2025. The deal aims to enhance SciSparc’s industry positioning by leveraging Miza’s platform, potentially increasing its equity interest in Miza to 84% upon achieving certain milestones. Miza plans to rename itself to NeuroThera Labs Inc. and expand its operations in the pharmaceutical and supplemental sectors.
More about SciSparc Ltd.
SciSparc Ltd. is a company operating in the pharmaceutical and nutraceutical sectors, focusing on advanced clinical stage pharmaceutical portfolios. The company is involved in developing and commercializing innovative therapies targeting the central nervous system.
Average Trading Volume: 4,638,237
Technical Sentiment Signal: Sell
Current Market Cap: $5.63M
See more insights into SPRC stock on TipRanks’ Stock Analysis page.
